DexCom Inc. (NASDAQ:DXCM) finished Thursday with a subtraction of -$3.4 to close at $100.98, a downside of -3.26 percent. An average of 3,765,020 shares of common stock have been traded in the last five days. There was a fall of -$6.83 in the past week, and it reached a new high 23 times over the past 12 months. The last 20 days have seen an average of 3,764,115 shares traded, while the 50-day average volume stands at 3,139,464.
DXCM stock has decreased by -22.73% in the last month. The company shares reached their 1-month lowest point of $100.78 on 08/24/23. With the stock rallying to its 52-week high on 07/28/23, shares of the company touched a low of $78.94 and a high of $139.55 in 52 weeks. It has reached a new high 21 times so far this year and lost -10.83% or -$12.26 in price. In spite of this, the price is down -27.64% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
DXCM stock investors should be aware that DexCom Inc. (DXCM) stock had its last reported insider trading activity 2 days ago on Aug 23. In this transaction, the insider spent $43,989. EVP Chief Financial Officer, Sylvain Jereme M, disposed of 1,844 shares at a price of $104.38 on Aug 22. The insider now owns more than $192,477 worth of shares. Prior to that, EVP Chief Human Resources Offi Stern Sadie went on to Sale 392 shares at $110.71 each on Aug 09. An amount of $43,398 was transacted.
Valuation Metrics
DexCom Inc. (DXCM) has a trailing price-to-earnings (P/E) ratio of 120.50. The stock’s beta is 1.12. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 12.45, the price-to-book (PB) ratio at 18.60, and the price-to-cash flow ratio at 85.45.
Financial Health
The quick ratio of DexCom Inc. for the three months ended June 29 was 2.20, and the current ratio was 2.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.19 and a total debt to equity ratio of 1.55 for the quarter ending June 29. Its gross profit as reported stood at $1.88 billion compared to revenue of $2.91 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, DexCom Inc.’s return on assets was 6.30%.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $115.9 million in the quarter, while revenues of $48.6 million were grew 56.08%. The analyst consensus anticipated DexCom Inc.’s latest quarter earnings to come in at $0.23 per share, but it turned out to be $0.34, a 47.80% surprise. For the quarter, EBITDA amounted to $171.8 million. Shareholders own equity worth $387.87 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at DexCom Inc. (DXCM) price momentum. RSI 9-day as of the close on 24 August was 24.38%, suggesting the stock is oversold, with historical volatility in this time frame at 35.11%.
As of today, DXCM’s price is $104.61 -6.34% or -$6.83 from its 5-day moving average. DXCM is currently trading -21.94% lower than its 20-day SMA and -13.08% lower than its 100-day SMA. However, the stock’s current price level is -19.83% below the SMA50 and -12.10% below the SMA200.
The stochastic %K and %D were 5.57% and 5.54%, respectively, and the average true range (ATR) was 3.93. With the 14-day stochastic at 0.94% and the average true range at 4.02, the RSI (14) stands at 27.99%. The stock has reached -3.92 on the 9-day MACD Oscillator while the 14-day reading was at -5.84.
Analyst Ratings
The consensus rating for DexCom Inc. (DXCM) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell DXCM, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 4 analysts, while 17 others rate it as a “buy”.
What is DXCM’s price target for the next 12 months?
Analysts predict a range of price targets between $130.00 and $175.00, with a median target of $150.00. Taking a look at these predictions, the average price target given by analysts for DexCom Inc. (DXCM) stock is $149.79.
